Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
Recent findings from the ASCO Gastrointestinal Cancers Symposium 2024 underscore the potential of innovative therapeutic combinations in enhancing outcomes for hepatocellular carcinoma patients, particularly those with unresectable or high-risk disease.
Oncology, Medical February 12th 2024
Mayo Clinic
In a significant advancement, one physician’s minimally invasive technique for treating membranous urethral strictures post-radiation therapy showcases promising outcomes, including improved urethral patency and reduced operative complications, marking a pivotal shift in patient management strategies.
Urology February 5th 2024
OBR Oncology
In the phase 3 GETUG-AFU 18 trial, high-dose radiotherapy (80 Gy) combined with long-term androgen deprivation therapy markedly improved 10-year progression-free and overall survival in high-risk prostate cancer patients, without additional toxicity.
Oncology, Medical February 5th 2024
Recent findings indicate that pre-WBRT administration of bevacizumab, etoposide, and cisplatin (BEEP) may significantly improve brain-specific progression-free survival in breast cancer patients with brain metastases.
Oncology, Medical January 16th 2024
UT Southwestern Medical Center
UT Southwestern’s pioneering use of SCINTIX biology-guided radiotherapy represents a major advancement in precision oncology, targeting bone and lung cancers with a novel approach that combines PET imaging and radiotherapy for more effective treatment.
Oncology, Radiation January 16th 2024
Oncology Learning Network
Highlighting a paradigm shift in breast cancer treatment, the NRG Oncology/NSABP B-51/RTOG 1304 study demonstrates that certain patients with node-negative breast cancer post-neoadjuvant chemotherapy may safely omit adjuvant regional nodal irradiation, challenging conventional treatment approaches and potentially improving patient quality of life.
Oncology, Medical January 8th 2024